Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Kadcyla (Trastuzumab Emtansine) for Treatment of Breast Cancer

Drug Name (Brand / Generic)

Kadcyla / trastuzumab emtansine

Company / Licensee

Genentech (a member of the Roche Group)

Therapy Class

Antibody-drug conjugate (ADC)

Current Indication

Breast cancer

Market Sector

Oncology

Development Status

Approved in the US and Japan
Expand
Close
Close
Close

Go Top